Author | Year | Disease | Country | Sample size | Over-expression (N, %) | Detection method | Evaluation standard of TRIM44 overexpression | End-points (analysis type) | Follow-up | NOS score |
---|---|---|---|---|---|---|---|---|---|---|
Kashimoto K | 2012 | GC | Japan | 112 | 28, 25% | IHC | Final staining scoresa ≥ 4 | OS (M) | NR | 8 |
Kawabata H | 2017 | BC | Japan | 129 | 67, 52% | IHC | Final staining scoresa ≥ 5 | OS (M) | ≥ 5 years | 9 |
Kawaguchi T | 2017 | EC | Japan | 68 | 39, 57% | IHC | Final staining scoresb ≥ 1 | OS (M) | ≥ 5 years | 9 |
Li P | 2018 | EMC | China | 143 | 80, 56% | IHC | Final staining scoresa ≥ 4 | OS (C) | ≥ 5 years | 7 |
Liu S | 2018 | EOC | China | 109 | 93, 85% | IHC | Final staining scoresa ≥ 3 | OS (M), DFS (M) | ≥ 5 years | 7 |
Peng R | 2018 | ICC | China | 130 | 71, 55% | IHC | Percentage of TRIM44 positive cells ≥50% | OS (M) | ≥ 5 years | 8 |
Xing Y | 2016 | NSCLC | China | 331 | 208, 63% | IHC | Final staining scoresc ≥ 4 | OS (M), DFS (M) | ≥ 5 years | 9 |
Xiong D | 2018 | EC | China | 100 | 53, 53% | IHC | Final staining scoresc ≥ 4 | OS (M) | ≥ 5 years | 8 |
Yamada Y | 2017 | TGCT | Japan | 103 | 41, 40% | IHC | Intensity score ≥ 1 | NR | NR | 7 |
Zhu X | 2016 | HCC | China | 106 | 73, 69% | IHC | Final staining scoresc ≥ 5 | OS (M) | ≥ 5 years | 8 |
Liu S | 2019 | CC | China | 122 | 81, 66% | IHC | Final staining scoresa ≥ 3 | OS (M), DFS (M) | ≥ 5 years | 7 |
Wei CY | 2019 | Melanoma | China | 197 | 98, 50% | IHC | integrated optical density value(≥ median value) | OS (M), DFS (M) | ≥ 5 years | 7 |
Wang H | 2018 | Osteosarcoma | China | 90 | 53, 58.9% | IHC | Final staining scores a > 5 | NR | NR | 8 |